Background: Oral and sublingual immunotherapies for peanut allergy have demon-
| INTRODUCTION
Peanut allergy is a major public health concern affecting 1% of the US and European populations, rising in prevalence, and outgrown in only 20% of those affected with the disease. [1] [2] [3] Although there are no FDA-or EMA-approved treatments for peanut allergies, extensive investigation has focused on the use of several immunotherapy approaches. Emerging peanut allergy therapies include oral immunotherapy (OIT), [4] [5] [6] sublingual immunotherapy (SLIT) 7, 8 and epicutaneous immunotherapy (EPIT), 9, 10 among others. 11 While routes, doses and duration vary for each form of therapy, these therapies all expose the allergic subject to increasing quantities of peanut protein over a period of months to years.
OIT and SLIT have been effective at inducing both short-lived desensitization (defined as an increased allergen threshold while taking therapy daily) and sustained unresponsiveness (SU) (defined as an absence of allergic symptoms during challenge after stopping therapy). 5, 12 However, no confirmed biomarkers exist to identify which subjects will achieve SU and which will be transiently desensitized.
Despite the promising clinical findings, the mechanisms by which OIT and SLIT alter the immune system and result in desensitization or SU remain unclear. Skin prick test data and mechanistic studies have previously shown that peanut immunotherapies promote mast cell and basophil hyporesponsiveness 4, 13, 14 as well as an increase in regulatory T cells. 4, 14, 15 Extensive work by our group and others has demonstrated that peanut-specific IgE (PN-sIgE) levels often transiently increase on OIT and SLIT within a few months of starting therapy but are significantly decreased after many months or years of therapy. 4 It is important to note that PNsIgE levels are uncoupled from desensitization as observed when PN-sIgE is increased from baseline but clinical reactivity and mast cell and basophil degranulation has diminished. 16 OIT and SLIT both cause a significant increase in levels of peanut-specific IgG4 (PNsIgG4) though these quantities alone have not been shown to be predictive of SU vs desensitization. 6, 12 Oral immunotherapy and SLIT are known to result in increased antigen-specific IgG, and particularly IgG4, which are antibodies known to block IgE-mediated reactions, even in the presence of persistent levels of IgE. Previous work has shown that serum from subjects on peanut OIT inhibits facilitated antigen binding, suggesting that a plasma factor has antigen-specific blocking capabilities. 6 Two recent studies have investigated the functional role of IgG in the context of effector cell inhibition. In the first, LAD2 mast cells passively sensitized with plasma from peanut-allergic subjects exhibited greater activation following peanut stimulation than those passively sensitized with plasma from peanut-sensitized but tolerant subjects, which had higher levels of PN-sIgG4. 17 Furthermore, plasma from subjects on peanut OIT was able to block mast cell activation and removal of IgG partially abrogated these findings. Similarly, a second study demonstrated that sera from mice on OVA OIT or humans on peanut OIT suppressed activation of sensitized bone marrow mononuclear cells or basophils, respectively. 18 Inhibition of these effector cells was further shown to be dependent on the inhibitory receptor FcγRII.
In our present study, we definitively demonstrate that OITinduced changes in IgG lead to suppression of basophil activation to peanut. We also compared the inhibitory effects of plasma from subjects on peanut OIT and SLIT and on different durations of therapy. Finally, we sought to determine whether basophil inhibition caused by plasma transfer can be used to distinguish subjects that experience desensitization from those that experience SU on peanut OIT or SLIT.
| METHODS

| Clinical trials
OIT and SLIT studies were IRB approved and study drug administered under INDs. 19 OIT Trial #1 listed below was designed with the primary goal of assessing SU after several years on therapy, while OIT Trial #2 was focused on desensitization with a shorter treatment duration. The doses defining SU were chosen based on our understanding of the effectiveness of these therapies at the time of trial implementation. The details provided below are relevant to the present studies on blocking antibodies.
OIT Trial #1 (Clinical trial #s: NCT00815035, NCT00597675):
Peanut-allergic subjects were randomized to peanut OIT or placebo.
Doses started at 0.1 mg and reached maintenance doses of 4000 mg protein. Subjects on placebo crossed-over to active treatment after 12 months. After 48 months of active treatment, subjects underwent an oral food challenge (OFC) to assess desensitization.
Subjects were taken off therapy for up to 3 months before undergoing an OFC to assess SU. For the purpose of these experiments, a cut-off of 5000 mg peanut protein was used to define SU.
OIT Trial #2 (NCT01814241):
Peanut-allergic subjects were given open-label peanut OIT up to 1450 mg. After 6 months of active treatment, subjects underwent an OFC to assess desensitization.
Subjects were taken off therapy for up to 1 month before undergoing an OFC to assess SU. For the purpose of these experiments, a cut-off of 3750 mg peanut protein was used to define SU.
SLIT (NCT00597727):
Peanut-allergic subjects received peanut SLIT. Maintenance doses reached 2 mg protein. After 60 months of active treatment, subjects underwent an OFC to assess desensitization. Subjects were taken off therapy for 1 month before undergoing an OFC to assess SU. For the purpose of these experiments, a cutoff of 1750 mg peanut protein was used to define SU.
| Plasma samples
For each of these studies, venous blood was drawn into sodiumheparin tubes. Whole blood was centrifuged and plasma collected. 
| Basophil activation and inhibition assays
For basophil assays on blood from peanut-allergic donors, 200 μL whole blood was centrifuged at 300 g for 10 minutes. Peanut extract was prepared in-house using Golden Peanut flour (Alpharetta, GA) as described previously. 20 For each assay, a negative control consisting of blood from the allergic donor stimulated with RPMI and IL-3 was used to confirm that cells were not being acti- Figure S1 .
For passive sensitization of basophils from a non-allergic donor ( Figures 3 and 4) , whole blood from a donor with no known allergies was centrifuged at 300 g for 10 minutes. The plasma from the nonallergic donor was removed and replaced with pooled plasma from peanut-allergic subjects. These pools were created by adding equal parts of plasma from 2 to 3 subjects on OIT Trial #2 and had an average PN-sIgE of 327.98 kU/L and an average PN-sIgG4 of 0.50 μg/mL. Cells were incubated with the pooled plasma from allergic subjects for 2 hours at 37°C and 5% CO 2 and mixed every 30 minutes. Following passive sensitization, blocking plasma from subjects on OIT or SLIT were applied and cells stimulated, stained and analysed as described above.
| Statistical analyses
GraphPad/Prism version 7.02 was used to analyse all data. MannWhitney U, Wilcoxon and paired and unpaired t tests were performed and a P-value < 0.05 was considered significant. Percent inhibition of basophil activation was calculated by subtracting the % CD63 + basophils in the presence of OIT or SLIT plasma from the % CD63 + basophils at baseline, dividing by the %CD63 + basophils at baseline and then multiplying by 100%.
| RESULTS
| Plasma from subjects on peanut OIT, but not placebo, inhibits peanut-stimulated basophil activation
Plasma from peanut-allergic subjects was removed and replaced with plasma from subjects on either 0 months or 12 months of peanut OIT as shown in the schematic in Figure 1A . Following stimulation with peanut extract, activated basophils (CD123 + CD203c + Lymphocytes) were identified by upregulation of cell-surface CD63
( Figure 1B ). Incubation with 12-month active OIT plasma resulted in decreased basophil activation compared to incubation with autologous 0-month plasma (P < 0.0001); however, this blocking of basophil activation was not observed in basophils incubated with plasma from subjects on 12 months of placebo ( Figure 1C ). This inhibition capability was accompanied by small decreases in PN-sIgE (P < 0.05, Figure 1D ) and larger increases in PN-sIgG4 (P < 0.05, Figure 1E ).
Similarly, we investigated the inhibition capabilities of plasma from subjects who started on 12 months of placebo before crossing over to active OIT. Basophils incubated with plasma from 12 months of active therapy inhibited basophil activation (P < 0.01), whereas plasma from the same subjects while on placebo had no effect on basophil activation compared to baseline plasma ( Figure 1F ). Taken
together, these results demonstrate that OIT-induced changes in plasma can block basophil activation.
Due to limited plasma volumes for use in further experiments, we tested the ability of pooled 12-month OIT plasma to block basophil activation. Consistent with the findings for basophils incubated with individual OIT plasma, basophils incubated with pooled OIT plasma had decreased activation (P < 0.001, Figure S2 ). These findings show that pooled plasma can be used to further study the inhibitory effect on basophils. As a result, pooled plasma was used for the experiments in Figure 2 . Figure S3A ) and PN-sIgG4 (P < 0.01, Figure S3B ) levels were decreased to <1 μg/mL following depletion with Protein A/G beads compared to sham depletion. PN-sIgE levels also decreased with depletion, although IgE was readily detectable and decreases were modest ( Figure S3C ). The ratio of PN-sIgE to PN-sIgG4 increased with depletion compared to sham depletion, though changes were not significant ( Figure S3D ). These results suggest that the depletion had a greater effect on IgG and IgG4 than IgE, as expected. Basophils incubated with either undiluted or sham-depleted 12-month OIT plasma had decreased activation compared to baseline (0 mo) plasma (P < 0.01) (Figure 2A ). This inhibition was abrogated by IgG depletion (P < 0.01, Figure 2A ), demonstrating that OIT-induced IgG is critical for the blocking of basophil activation, consistent with the findings of others. 17, 18 We further demonstrated the importance of IgG by using the IgG fraction enriched from OIT subject plasma to block basophil activation. Incubating IgE-sensitized basophils with IgG-depleted plasma did not inhibit basophil activation, while incubating with the IgG fraction substantially blocked basophil activation (P < 0.01, Figure 2B ).
| OIT and SLIT subjects' plasma have similar basophil inhibition capacity
Due to limited availability of basophils from peanut-allergic donors,
we developed an assay to passively sensitize basophils from nonallergic donors ( Figure 3A) . In this assay, the plasma from a non-allergic subject was replaced by pooled plasma from peanut-allergic subjects. Prior to this passive sensitization protocol, the donor's basophils were not activated upon stimulation with peanut extract; however, they can be activated with peanut stimulation following incubation with plasma from allergic subjects, and activation can be blocked with OIT plasma ( Figure 3B ). Using this tool, we sought to determine if the plasma from subjects on OIT and SLIT had similar effects on basophil activation. Surprisingly, plasma from a 6-month OIT regimen had a greater inhibition effect on basophils than plasma from a 48-month OIT regimen (P < 0.01, Figure 3C ), although both had >80% median inhibition. Both had similar levels of PN-sIgG4, but the 48-month OIT plasma samples had significantly less PN-sIgE ( Figure 3D ,E). Similar inhibition of basophil activation was observed for plasmas from 6 months of OIT and SLIT ( Figure 3F ). These samples contained similar levels of PN-sIgE, but the OIT samples had higher levels of PN-sIgG4 ( Figure 3G,H) . Plasma from the time of desensitization challenge (6 months for OIT and 60 months for SLIT) while subjects were still on therapy demonstrated no difference in blocking ability when incubated undiluted with basophils ( Figure 3I ).
Diluting the plasma 1:4 in PBS resulted in decreased basophil inhibition for SLIT plasma compared to OIT plasma (P < 0.05, Figure 3I ).
Despite these functional differences, PN-sIgG4 levels were higher and PN-sIgE samples were lower in SLIT samples compared to OIT samples ( Figure 3J ,K), indicating that functional blocking capacity is not strictly related to PN-sIgG4 and PN-sIgE quantities.
| Extent of basophil inhibition by OIT, but not SLIT, plasma is associated with clinical outcomes following therapy
Ex vivo basophil activation has previously been shown to decrease on OIT but does not discriminate subjects who achieve SU from those that are desensitized. 21 We sought to determine whether the immunotherapy-induced plasma inhibition of donor basophils can be useful in distinguishing or predicting these clinical outcomes following either OIT or SLIT. When used undiluted, plasma from OIT subjects at the time of desensitization challenge who were later classified as SU did not induce a different percent inhibition than plasma from subjects who would later be identified as transiently desensitized ( Figure 4A) . Similarly, inhibition of basophil activation was not different between plasma from SU and desensitized subjects at the time of tolerance challenge after discontinuing OIT (Figure 4B) . Nevertheless, when OIT plasma from the time of desensitization challenge was diluted 1:10 or 1:50, plasma from SU subjects had a greater percent inhibition than that from desensitized subjects, suggesting that this assay may be useful in predicting clinical outcomes after stopping therapy (P < 0.05, Figure 4C ). Plasma PN-sIgE levels were not different between groups at either challenge timepoint, though levels tended to be lower in the group that experienced SU ( Figure 4D ). Conversely, PN-sIgG4 levels were higher in the subjects who experienced SU than those who were desensitized ( Figure 4E ). Interestingly, these quantity differences were not significant at the time of desensitization challenge, when the functional differences were noted ( Figure 4C ). Despite these interesting findings from OIT samples, undiluted or diluted plasma samples from the time of desensitization challenge while on SLIT had no significant difference in percent inhibition of basophil activation for subjects who achieve SU compared to those that achieve desensitization;
however, the sample size limits statistical power ( Figure 4F ). PN-sIgE and PN-sIgG4 levels were not different between SLIT outcomes ( Figure 4G,H) . Together, these results suggest that inhibition of basophil activation may be a mechanism for SU following OIT, and that PN-sIgG4 is likely not the only isotype involved in the basophil inhibition process.
| DISCUSSION
Oral immunotherapy and SLIT are two promising investigational therapies for peanut allergy with a substantial number of subjects demonstrating desensitization, and in some cases SU, however key knowledge gaps remain. There is currently no way to predict which subjects will have success with OIT or SLIT or how long protection persists after subjects discontinue therapy. Further, immunotherapyinduced immune change(s) that can distinguish subjects who achieve SU from those that are transiently desensitized, have yet to be identified. Finally, the mechanisms by which OIT and SLIT induce desensitization and SU have not been fully elucidated. Here, we demonstrated that plasma from subjects on OIT and SLIT can inhibit basophil activation, a potentially important mechanism of desensitization and SU. F I G U R E 3 Oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) plasma basophil inhibition capability. Schematic for use of nonallergic donor basophils incubated with peanut-allergic plasma in the basophil activation assay (A) and representative results (B). Percent inhibition following incubation with plasma at the time of tolerance challenge for a 6-mo OIT and 48-mo OIT regimen (C) and corresponding PN-sIgE (D) and PN-sIgG4 (E) levels. Percent inhibition following incubation with plasma following 6-mo OIT or 6-mo SLIT (F) and corresponding PN-sIgE (G) and PN-sIgG4 (H) levels. Percent inhibition following incubation with undiluted and diluted 6-mo OIT or 60-mo SLIT plasma (I) and corresponding PN-sIgE (J) and PN-sIgG4 (K) levels. Individual data are shown in C, F and I; red lines indicate medians; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Several reports have described inhibition of ex vivo basophil activation following OIT for peanut, milk, and egg; however, it is not clear how this effector cell desensitization occurs. We used plasma from subjects on OIT or placebo to demonstrate that OIT-induced changes in plasma, that are at least partly IgG-dependent can inhibit basophil activation in response to peanut stimulation. We further Off therapy
On therapy
This report is also the first to relate the degree to which plasma from OIT or SLIT inhibits basophil activation to clinical outcomes following completion of therapy. Basophil inhibition by undiluted plasma from subjects on 48 months of OIT was not predictive of which subjects would develop SU after time off therapy. In fact, even basophil inhibition by undiluted plasma at the time of tolerance challenge was not different between subjects who experienced SU from those who were transiently desensitized. However, the inhibition effect of diluted plasma from subjects at the time of desensitization challenge was indicative of which subjects would later be classified as SU and which would be classified as desensitized after discontinuing therapy. Interestingly, PN-sIgG4 quantities were not different at this challenge time-point between subjects who experienced SU from those who were desensitized, signifying that it is not just the quantity of PN-sIgG4, but perhaps functional changes that are important for the development of SU. Importantly, these findings were true for plasma samples from the time of desensitization challenge, suggesting that the percent inhibition of basophils by diluted plasma while still on OIT may eventually be useful as a predictive marker for subjects that will develop SU. On the other hand, basophil inhibition by plasma from subjects on 60 months of peanut SLIT was not associated with clinical outcome even when samples were diluted. Taken together, these results suggest that the mechanisms for the induction of SU may differ between OIT and SLIT.
The possible applications for the assays and findings presented here have valuable potential for food allergy research and more broadly, allergen immunotherapy studies. The assay using passively sensitized cells is a useful tool to analyse the functional changes in triggering an inhibitory rather than activating signal. 23, 24 Other forms of immunotherapy including subcutaneous immunotherapy for bee venom 25 and grass pollen 26, 27 induce an increase in IgG4 that intercepts antigen, preventing it from binding to cells. A previous study
showed that peanut OIT-induced IgG acts through the IgG receptor, FcγRII on basophils to inhibit their activation. 18 Future experiments are needed to determine intrinsic cellular changes in subjects actively undergoing immunotherapy in addition to the plasma changes observed in these studies. For example, we have previously demonstrated impaired calcium flux due to actin rearrangement following desensitization in model systems. 28 The findings also assist in the understanding of the changes that distinguish subjects that develop SU. As a result, if the findings are replicated in larger experiments we may be able use these basophil inhibition assays to determine if a subject needs to be on therapy for a longer period of time. More broadly, the improved understanding of immunotherapy mechanisms will allow for targeted therapies in the future.
